

Research article

# **Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination**

Suvichada Assawakosri<sup>a,b</sup>, Sitthichai Kanokudom<sup>a,b</sup>, Nungruthai Suntronwong<sup>a</sup>, Jira Chansaenroj<sup>a</sup>, Chompoonut Auphimai<sup>a</sup>, Pornjarim Nilyanimit<sup>a</sup>, Preeyaporn Vichaiwattana<sup>a</sup>, Thanunrat Thongmee<sup>a</sup>, Thaneeya Duangchinda<sup>c</sup>, Warangkana Chantima<sup>d,e</sup>, Pattarakul Pakchotanon<sup>c</sup>, Donchida Srimuan<sup>a</sup>, Thaksaporn Thatsanatorn<sup>a</sup>, Sirapa Klinfueng<sup>a</sup>, Natthinee Sudhinaraset<sup>a</sup>, Nasamon Wanlapakorn<sup>a</sup>, Juthathip Mongkolsapaya<sup>f,g</sup>, Sittisak Honsawek<sup>b,\*\*</sup>, Yong Poovorawan<sup>a,h\*</sup>

<sup>a</sup> Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand

<sup>b</sup> Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand

<sup>c</sup> Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, NSTDA, Pathum Thani 12120, Thailand

<sup>d</sup> Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>e</sup> Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>f</sup> Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK

<sup>g</sup> Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

<sup>h</sup> FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand

\*Correspondence: Prof. Yong Poovorawan, MD. Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University. Bangkok, 10330 Thailand. E-mail: [yong.p@chula.ac.th](mailto:yong.p@chula.ac.th)

\*\*Correspondence: Prof. Sittisak Honsawek, MD. Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand E-mail: [sittisak.h@chula.ac.th](mailto:sittisak.h@chula.ac.th)

Main text: 3327 words

Abstract: 218 words

## Highlights

- The persistence of antibody responses is different among three vaccine platforms.
- Highly remained antibody levels were observed with the mRNA and viral vector booster.
- The half-dose mRNA-1273 can be used interchangeably with the full-dose mRNA-1273.
- The neutralizing activity against BA.5 was lower than wild type and BA.2 subvariant.
- A fourth dose is recommended for individuals who received an inactivated booster.

1 **Abstract**

2 **Objectives:** Several countries have authorized a booster vaccine campaign to combat the spread  
3 of COVID-19. Data on persistence of booster vaccine-induced immunity against new Omicron  
4 subvariants are still limited. Therefore, our study aimed to determine the serological immune  
5 response of COVID-19 booster after CoronaVac-priming.

6 **Methods:** A total of 187 CoronaVac-primed participants were enrolled and received an  
7 inactivated (BBIBP), viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2,  
8 full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both  
9 binding and neutralizing antibodies against wild-type and Omicron was determined on day 90–  
10 120 after booster.

11 **Results:** A waning of total RBD immunoglobulin (Ig) levels, anti-RBD IgG, and neutralizing  
12 antibodies against Omicron BA.1, BA.2, and BA.4/5 variants was observed 90–120 days after  
13 booster vaccination. Participants who received mRNA-1273 had the highest persistence of the  
14 immunogenicity response, followed by BNT162b2, AZD1222, and BBIBP-CorV. The responses  
15 between full and half doses of mRNA-1273 were comparable. The percentage reduction of  
16 binding antibody ranged from 50% to 75% among all booster vaccine.

17 **Conclusions:** The antibody response substantially waned after 90–120 days post-booster dose.  
18 The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of  
19 humoral immune responses against the Omicron variant compared to the inactivated BBIBP  
20 booster. Nevertheless, an additional fourth dose is recommended to maintain immune response  
21 against infection.

- 22 **Keywords** COVID-19 vaccine; durability; CoronaVac; heterologous booster; neutralizing  
23 antibody; Omicron.

## 24        **1. Introduction**

25            With the ongoing coronavirus disease 2019 (COVID-19) pandemic, the emerging  
26    Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is  
27    considered more transmissible than other previous variants of concern, including Alpha, Beta,  
28    and Delta variants (Kumar et al., 2022). Therefore, vaccination is an essential tool to alleviate the  
29    spread of the COVID-19 pandemic. The inactivated virus vaccine platform is one of the most  
30    widely used as primary regimen among all COVID-19 vaccines. CoronaVac (Sinovac Biotech  
31    Co., Ltd., Beijing, China) is one of a whole inactivated virus COVID-19 vaccines that have been  
32    approved for use in more than 56 low- and middle-income countries around the world, including  
33    Thailand (COVID-19 tracker, 2022). Nevertheless, several studies have demonstrated that the  
34    neutralization of the Omicron variant was highly limited in sera from those who received the  
35    primary series of COVID-19 vaccines, for either the mRNA or viral vector or inactivated  
36    platforms (Edara et al., 2022, Lu et al., 2022, Muik et al., 2022, Planas et al., 2022). Therefore,  
37    the use of third dose COVID-19 vaccines has been recommended by the US Food and Drug  
38    Administration to combat the new Omicron variant (Centers for Disease Control and Prevention,  
39    2022).

40            In late December 2021, a mass booster dose vaccination campaign was first  
41    recommended in Thailand by the Ministry of Public Health, especially for adults previously  
42    vaccinated with two doses of CoronaVac. Recently, we reported the results of a third dose  
43    booster study in healthy adults previously primed with two doses of CoronaVac. Our finding  
44    showed that a third heterologous dose elicited a robust immune response against the Omicron  
45    variant (Assawakosri et al., 2022b, Kanokudom et al., 2022b). Moreover, a booster with  
46    BNT162b2 in CoronaVac-primed individuals improved vaccine effectiveness (VE) to 92.7% for

47 protection against COVID-19 infection in Brazil (Cerqueira-Silva et al., 2022b). A significant  
48 challenge in controlling the COVID-19 pandemic is the waning of vaccine-induced immunity. A  
49 previous COV-boost study reported the decline in immunogenicity three months after the third  
50 dose using viral vector platforms, AZD1222 (AstraZeneca, Oxford, UK) (Liu et al., 2022).  
51 However, it is currently unclear on immunogenicity beyond one month following the third  
52 heterologous dose in CoronaVac-primed individuals as is how rapidly protection from booster  
53 dose wanes over time.

54         Subvariants of the Omicron are continuously emerging during the COVID-19 pandemic.  
55 Initially, Omicron variants were categorized into several descendent subvariants, including BA.1,  
56 BA.1.1, BA.2, BA.2.2, and BA.3 (Viana et al., 2022; Yamasoba et al., 2022). Subsequently, two  
57 new Omicron subvariants that harbor the L452R spike protein mutation have been designated as  
58 BA.4 and BA.5 (Tegally et al., 2022). Both BA.4 and BA.5 have identical spike protein  
59 sequences (hereafter BA.4/5) (Zhou et al., 2022). A previous study showed that the BA.4/5  
60 subvariants are more pathogenic than BA.1 and are highly resistant to BA.1 and BA.2-infected  
61 sera (Kimura et al., 2022). Furthermore, BA.4/5 exhibited an 18.3-fold higher infectivity rate  
62 than that observed in BA.2 (Zhou et al., 2022). However, there are limited data on BA.4/5  
63 immune evasion in third-dose heterologous vaccinated individuals. Therefore, the present study  
64 aimed to evaluate the durability of immune protection at three to four months following four  
65 different heterologous booster vaccines in adults who completed a two-dose CoronaVac. In  
66 addition, we also investigated immunogenicity against the newly emerging Omicron variants  
67 BA.2 and BA.4/5 subvariants.

## 68        **2. MATERIALS AND METHODS**

### 69        **2.1 Study design and participants**

70        The study protocol was described in our previous studies (Assawakosri et al., 2022b,  
71        Kanokudom et al., 2022b). Briefly, this study was a prospective cohort study of heterologous  
72        third-dose vaccination. All participants were Thai adults over 18 years of age with no previous or  
73        current diagnosis of COVID-19 infection and who had received the CoronaVac 2-dose vaccine  
74        (Sinovac Biotech Co., Ltd., Beijing, China) with the 6±1 months interval period. All participants  
75        were allocated to receive a booster dose of the COVID-19 vaccine, including BBIBP-CorV,  
76        AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-dose). The study flow  
77        is illustrated in Figure 1. This study was conducted in the Clinical Trial Unit, the Center of  
78        Excellence in Clinical Virology of Chulalongkorn University, Bangkok, Thailand. The study was  
79        approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn  
80        University (IRB numbers 546/64 and 498/65). The study was registered with the Thai Registry of  
81        Clinical Trials (TCTR 20210910002). Written informed consent was obtained from each  
82        participant before the enrollment and this cohort study was conducted in accordance with the  
83        Declaration of Helsinki.

### 84        **2.2 Study vaccine**

85        The study vaccines were as follows: inactivated: BBIBP-CorV (Sinopharm, Beijing, China),  
86        viral vector: AZD1222 (AstraZeneca, Oxford, UK), mRNA: 30 µg BNT162b2 (full-dose group)  
87        and 15 µg (half-dose group) (Pfizer-BioNTech Inc., New York City, NY, USA), mRNA: 100 µg  
88        mRNA-1273 (full-dose group) (Moderna Inc., Cambridge, MA, USA), and 50 µg mRNA-1273  
89        (half-dose group).



### 90 **2.3 Sample collection**

91 Peripheral venous blood samples (10–15 mL) were collected on day 28, and 90 to 120 after  
92 vaccination. The clot blood tubes were then centrifuged at 2000 rpm for 10 minutes at room  
93 temperature to collect serum samples. All specimens were stored at -20°C until further analysis.

### 94 **2.4 Total RBD Ig, anti-RBD IgG, and anti-nucleocapsid assay**

95 Serum samples were used to measure total immunoglobulin (Ig) specific for the RBD of SARS-  
96 CoV-2 using an electrochemiluminescence immunoassay—Elecsys SARS-CoV-2 S (Roche  
97 Diagnostics, Basel, Switzerland)—according to the manufacturer’s instructions and as previously  
98 described (Kanokudom et al., 2022). The Ig titer was determined as unit per milliliter (U/mL),  
99 and the level  $\geq 0.8$  U/mL was considered a positive detection.

100 The levels of IgG specific to an RBD and nucleocapsid protein of the SARS-CoV-2 virus in  
101 serum samples were detected by the chemiluminescence microparticle immunoassay (Abbott,  
102 Sligo, Ireland). Anti-RBD IgG is a quantitative assay with a limit of detection level at  $\geq 21$   
103 AU/mL, a lower level of less than 50 AU/mL is considered a negative result. While the Anti-  
104 nucleocapsid IgG is a semi-quantitative technique, the level  $\geq 1.4$  sample/cutoff (S/C) was  
105 defined as positive detection.

### 106 **2.5 Surrogate virus neutralization assay for Wuhan and Omicron variants**

107 Neutralizing activities against wild type (Euroimmun, Lubeck, Germany) and a cPass™ SARS-  
108 CoV-2 surrogate virus neutralization test (sVNT) (GenScript Biotech, Piscataway, NJ, USA)  
109 were used to measure NAb titers against SARS-CoV-2 variants. Recombinant RBD of Omicron;  
110 BA.2 strains (G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N,  
111 T478K, E484A, Q493R, Q498R, N501Y, Y505H) and BA.4/5 strains (G339D, S371F, S373P,  
112 S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V,

113 Q498R, N501Y, Y505H) were incubated in 96-well plates coated with recombinant human  
114 ACE2 and the sera sample of vaccinees. Samples with a percentage inhibition (% inhibition)  
115 greater than or equal to 35% threshold for wild type and greater than or equal to 30% for the  
116 Omicron BA.2 and BA.4/5 subvariants were considered 'seropositive' for SARS-CoV-2  
117 neutralizing antibodies (Kanokudom et al., 2022a).

## 118 **2.6 Focus reduction neutralization test (FRNT50) against the BA.1 and BA.2 variants**

119 Neutralization antibody titers were measured against BA.1 variants (accession number:  
120 EPI\_ISL\_8547017) and BA.2 (EPI\_ISL\_11698090) of the SARS-CoV-2 Omicron. The Focus  
121 reduction neutralization assay was performed as previously described (Assawakosri et al., 2022a,  
122 2022b). Additionally, the 50% focus reduction was calculated, and the half maximum inhibitory  
123 concentration (IC50) was determined using PROBIT regression analysis (SPSS Inc., Chicago,  
124 IL, USA). The detection limit of the assay is 1:20 and NAb values below the detection limit were  
125 substituted with a titer of 10.

## 126 **2.7 Statistical analysis**

127 All statistical analyses were performed using the Statistical Package for the Social Sciences  
128 (SPSS) v.22.0 (SPSS Inc., Chicago, IL, USA). Figures were generated using GraphPad Prism  
129 v9.0 (GraphPad Software, San Diego, CA, USA). The categorical data comparison, including sex  
130 and comorbidities, was performed using Pearson's chi-square test. Total RBD Ig, anti-RBD IgG,  
131 and NAb levels were reported as geometric mean titers (GMT) with a 95% confidence interval  
132 (CI). The geometric mean ratio of immunogenicity between day 90–120 and day 28 timepoints  
133 (GMR D90–120/28) was calculated using the GMT logarithmically transformed and was  
134 performed using a paired *t* test. Analysis of variance (ANOVA) with Bonferroni adjustment or  
135 Kruskal–Wallis H test (for nonparametric data) was used to compare independent groups. The

136 percentage inhibition of the surrogate neutralization assay and anti-nucleocapsid (N) IgG was  
137 calculated as the median with the interquartile range (IQR). A *P*-value of <0.05 (\*), <0.01 (\*\*),  
138 <0.001 (\*\*\*) was considered statistically significant.

### 139 **3. RESULTS**

#### 140 **3.1 Demographic data**

141 Of the 334 participants vaccinated with a different COVID-19 booster doses from two previous  
142 studies between September and November 2021, 187 participants were included in this long-  
143 term follow-up study with assessments on day 90 to 120. The demographic characteristics of this  
144 study are presented in Table 1. All participants were healthy Thai adults (well-control  
145 comorbidities were acceptable) between 20 and 69 years of age. The mean age (range) of  
146 participants was 40.8 (20–69), 43.7 (31–64), 45.0 (20–62), 40.8 (22–55), 40.6 (20–63), 36.7 (21–  
147 57), and 40.5 (20–69) for BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273  
148 (full- or half-dose), respectively. The average interval between the second and booster doses was  
149 160.7 (115–237) days. The baseline sex and comorbidities of the participants were comparable  
150 among all groups. Whereas the mean age of the mRNA-1273 group was significantly lower than  
151 other groups. Age was used for statistical adjustment. During the cohort period, two participants  
152 were excluded from the study due to anti-N IgG seroconversion on day 90 to 120 were suspected  
153 of COVID-19 infection.

#### 154 **3.2 Measurement of Total RBD Ig, Anti-RBD IgG, and Anti-N IgG**

155 Overall, after booster dose vaccination, there was a significant reduction in antibody levels, both  
156 total RBD Ig and anti-RBD IgG, on day 90 to 120. At 28 days after booster vaccination, the  
157 GMT of the total RBD Ig were 1231, 10,766, 21,240, 22,345, 36,845, and 28,087 U/mL for  
158 BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-dose),

159 respectively. Subsequently, the GMT of the total RBD Ig of six groups were decreased to 620,  
160 3984, 5514, 9722, 10,853, and 10,587 U/mL, respectively, at 90–120 days after booster dose.  
161 Among the six groups, the decay rate of total RBD Ig levels in the BBIBP group was lower than  
162 that in other groups, with a GMR D90–120/28 ratio of 0.50 (95% CI: 0.41–0.61). While the GMR  
163 D90–120/28 ratios were comparable in the mRNA booster groups with 0.26 (95% CI: 0.22–0.30)  
164 for BNT162b2 and 0.30 (95% CI: 0.27–0.32) for the mRNA-1273 group. Interestingly, a  
165 comparable decay rate was evident between half-dose and full-dose mRNA-1273. Similar trends  
166 were observed in anti-RBD IgG levels. The percentage reduction of each booster vaccine  
167 ranged from 50% to 75%, as shown in Table 2. In summary, individuals boosted with mRNA-  
168 1273 possessed the highest persistence of total RBD Ig and anti-RBD IgG among all booster  
169 groups, followed by half-dose mRNA-1273, half-dose BNT162b2, BNT162b2, AZD1222, and  
170 BBIBP, respectively.

### 171 **3.3 Surrogate virus neutralization-specific variants SARS-CoV-2 Wuhan, Omicron BA.2,** 172 **and BA.4/5**

173 A subset of 120 samples (20 samples/group) from day 90 to 120 was evaluated for surrogate  
174 neutralization activity against wild-type SARS-CoV-2, Omicron BA.2, and BA.5 subvariants.  
175 Most participants (85 to 100%) who had received the viral vector or the mRNA booster were  
176 seropositive for the wild type and (65% to 100%) for Omicron BA.2 and BA.4/5 subvariants. In  
177 contrast, only 61% and 20% to 40% of participants who received BBIBP booster presented  
178 seropositivity for wild type and Omicron BA.2 or BA.4/5 subvariants, respectively  
179 (Supplementary Table1). The median %inhibition of NAbs against the wild type remained higher  
180 than 95% for the viral vector and mRNA booster groups (Figure 2A). However, the median  
181 %inhibition of NAbs was substantially lower against the Omicron BA.2 subvariant at 26.8% in

182 BBIBP, 60.3% in AZD1222, 60.0% in BNT162b2, and 77.7% in the half-dose BNT162b2,  
183 75.4% in mRNA-1273, and 82.9% in the half-dose mRNA-1273 group (Figure 2B). Moreover, a  
184 reduction of %inhibition was also observed against the BA.4/5 subvariants with 15.6%, 50.2%,  
185 45.6%, 80.5%, 67.5%, and 79.6% in the six groups, respectively (Figure 2C). In summary, the  
186 median %inhibition of neutralizing activity against the Omicron variants BA.2 and BA.5, was  
187 lower than that observed against the wild type variant. While the median %inhibition of  
188 neutralizing activity against the BA.5 was 5% to 15% lower compared to that against the BA.2  
189 subvariant among all booster groups.

#### 190 **3.4 Focus reduction neutralization test against the BA.1 and BA.2 variants**

191 A subset of 20 samples from the AZD1222, BNT162b2, and mRNA-1273 groups on day 28 and  
192 day 90 to 120 was determined in the live virus focus reduction neutralization test (the BBIBP and  
193 the half-dose group were not included). Most of the participants (95% to 100%) on heterologous  
194 mRNA and viral vector booster schedules showed detectable NAbs on day 90 to 120. Previously,  
195 NAb GMTs against BA.1 were 243 for AZD1222, 313 for BNT162b2, and 645 for the mRNA-  
196 1273 groups at 28 days after the booster dose (Assawakosri et al., 2022b). Subsequently, the  
197 GMT of NAbs against BA.1 significantly decreased to 60.1, 82.6, and 133 in the three groups,  
198 respectively (Figure 3). While the NAbs GMTs against BA.2 were 340, 449, and 1035 in each  
199 group, which significantly dropped to 76.5, 70.5, and 229 in the AZD1222, BNT161b2 and  
200 mRNA-1273 groups, respectively. In comparison, the GMR D90–120/28 ratio of NAbs against  
201 BA.1 was approximately equal to the GMR D90–120/28 ratio of NAbs against BA.2. The  
202 percentage reduction among the three vaccines ranged between 70% and 85%, as shown in  
203 Supplementary Table 2. In accordance with those binding antibody levels, this finding

204 demonstrated that the neutralizing antibody significantly decreased on day 90 to 120 compared  
205 to day 28 after the booster dose.

#### 206 **4. Discussion**

207 In this study, we determined the persistence levels of binding antibodies and NAbS against the  
208 RBD of SARS-CoV-2 on day 90 to 120 after implementing COVID-19 booster dose vaccines  
209 that included BBIBP, AZD1222, BNT161b2 (full- or half-dose), and mRNA-1273 (full- or half-  
210 dose) in individuals primed with two doses of CoronaVac. Our findings revealed that boosting  
211 with the heterologous vaccine elicited high levels of total RBD Ig, anti-RBD IgG, and NAbS at  
212 28 days following booster vaccination. However, the antibody response substantially waned  
213 within three to four months after the booster dose, with a different pattern between each booster  
214 vaccine platforms. Additionally, consistent with the previous study in the United Kingdom, anti-  
215 spike IgG significantly decreased on day 84 after booster dose in participants who had previously  
216 been vaccinated with two doses of AZD1222 (Liu et al., 2022).

217 Total RBD Ig and anti-RBD IgG levels among all heterologous mRNA and viral vector booster  
218 vaccines highly remained on day 90 to 120 after vaccination. Conversely, binding antibody  
219 levels were lower in the BBIBP booster group. Among them, mRNA-1273 (full- and half-dose)  
220 demonstrated the highest level of total RBD Ig and anti-RBD IgG, while the decay rate of the  
221 mRNA-1273 booster was faster than that of the AZD1222 and BBIBP booster. Moreover, the  
222 decay rate of the binding antibodies was comparable between the full-dose and half-dose  
223 mRNA-1273 boosters. In agreement with the previous study of participants vaccinated with two  
224 doses of mRNA-1273 plus mRNA-1273 booster, the half-dose mRNA-1273 booster provided an  
225 antibody response similar to that of the full-dose booster (Choi et al., 2021). These results

226 suggest that the half-dose mRNA-1273 is interchangeable with the full-dose mRNA-1273 with  
227 no difference in decay rate.

228 Several studies have demonstrated that neutralizing antibody level is correlated with vaccine-  
229 induced immune protection against SARS-CoV-2 symptomatic disease (Earle et al., 2021;  
230 Favresse et al., 2022; Khoury et al., 2021; Koch et al., 2021). Therefore, a higher level of NAb  
231 may represent a higher percentage of vaccine efficacy against severe infection. After 90 to 120  
232 days post-vaccinated, we observed a high seropositive rate of NAb against the Omicron variant  
233 among participants who received heterologous mRNA and viral vector booster vaccines,  
234 especially mRNA-1273 vaccines. In line with a study in China that evaluated the use of the  
235 mRNA RQ3013 vaccine as the booster dose, mRNA booster provided the highest neutralizing  
236 antibodies against the omicron variant compared to other COVID-19 platforms (Zhang et al.,  
237 2022). In addition, we observed a comparable level of neutralizing antibodies against the BA.1  
238 and the BA.2 subvariants. In accordance with those observed in the previous study, the  
239 neutralizing antibody titers against the BA.2 subvariant were approximately equal to the BA.1  
240 subvariant and 1.7 times higher in participants with a homologous BNT162b2 booster (Chen et  
241 al., 2022; Kurhade et al., 2022).

242 The booster consisting of a heterologous mRNA and viral vector vaccine showed a higher  
243 seropositivity rate of neutralizing activity against BA.4/5, while the BBIBP booster achieved  
244 only 20% seropositivity. Similar to the study of three-dose CoronaVac and two-dose CoronaVac  
245 plus BNT162b2, the seropositive number of Plaque neutralizing antibody (PRNT50) against  
246 BA.4 and BA.5 was only 10% in homologous three-dose CoronaVac compared to 90–100% in a  
247 heterologous booster (Cheng et al., 2022). The results showed that the NAbS induced by  
248 heterologous mRNA and viral vector as a third dose vaccination had broad neutralizing activity

249 against several subvariants of SARS-CoV-2. Consistent with a previous study, after the  
250 homologous mRNA booster, the percentage of somatic hypermutated memory B cells increased  
251 and indicated B cell affinity maturation (Paschold et al., 2022). In comparison, the median  
252 %inhibition of neutralizing activity against Omicron BA.2 and BA.4/5 showed a significantly  
253 lower susceptibility than against wild type. Whereas the median %inhibition of neutralizing  
254 activity against BA.4/5 also demonstrated a lower trend than that of BA.2. Consistent with the  
255 50% neutralization titers against BA.4/5 data from homologous mRNA booster, BA.4/5 had  
256 lower neutralizing antibody titers than the BA.2.12.1 and D614G variants (Qu et al., 2022).  
257 These results indicated that the BA.4/5 subvariant exerts a higher vaccine-induced immune  
258 evasion and BA.4/5 certainly has overtaken other circulating subvariants.

259 Our findings showed that NAbs titers against the Omicron subvariant induced by the third dose  
260 booster waned over time, despite the fact that most participants had detectable NAbs on day 90  
261 to 120 after the booster dose. According to real-world VE data from Brazil, the estimated VE  
262 against symptomatic infection by the Omicron variant in participants who received a primary  
263 series of CoronaVac plus the BNT162b2 booster significantly decreased from 63.6% at day 14–  
264 30 to 1.7% at day 120 or more after the booster dose (Cerqueira-Silva et al., 2022a). Another  
265 study showed a decrease in VE from 57.3% at day 8–59 to 15.7% at day  $\geq 120$  after BNT162b2  
266 booster, while the VE in the homologous CoronaVac booster was only 8.1% at day 8–59 and  
267 decreased to -24.8% at day  $\geq 120$  post-boosted (Ranzani et al., 2022). However, the estimated VE  
268 against hospitalization and death remained highly effective, with 84.1% at day 120 or more after  
269 the booster dose. These results suggested that the third dose mRNA vaccine still achieved  
270 protection against severe disease, although it showed less protection against infection. However,



271 individuals with inactivated boosters may require additional booster doses with other vaccine  
272 platforms due to inadequate serological immune response and protection.

273 Our study has several limitations. First, due to the extension of the present study from the  
274 previous study cohort, almost 44% of all participants were lost to follow-up during the  
275 extended period at four-month follow-up timepoint. Second, the surrogate virus neutralization  
276 assay technique reached the upper detection limit for the wild type. Therefore, this method  
277 could not determine the exact NAb level. Lastly, data on the cellular immunity profile was not  
278 investigated. Data on the live virus neutralization test against other newly emerged BA.4/5 or  
279 BA.2.75 will be of great interest for further exploration.

## 280 **5. Conclusion**

281 At 90 to 120 days after third dose vaccination with the viral vector and mRNA in CoronaVac-  
282 primed individuals demonstrated high detectable rate of humoral immune responses both  
283 binding, and neutralizing antibodies against emerging Omicron BA.1, BA.2 and BA.4/5 SARS-  
284 CoV-2 subvariants. Nonetheless, real-world data has demonstrated a low percentage of VE  
285 against COVID-19 infection for individuals receiving any types of booster doses. To maintain  
286 the immune response against COVID-19 infection, a fourth booster dose is recommended for all  
287 groups, especially those who received the inactivated vaccine as the third dose booster.

288 **Declaration**

289 **Author contribution statement**

290 Suvichada Assawakosri: Conceived and designed the experiments; Performed the experiments;  
291 Analyzed and interpreted the data; Wrote the paper.

292 Sitthichai Kanokudom, Nungruthai Suntronwong, Jira Chansaenroj: Performed the experiments;  
293 Analyzed and interpreted the data.

294 Chompoonut Auphimai, Pornjarim Nilyanimit, Preeyaporn Vichaiwattana, Thanunrat  
295 Thongmee, Thaneeya Duangchinda, Warangkana Chantima, Pattarakul Pakchotanon Donchida  
296 Srimuan, Thaksaporn Thatsanatorn, Sirapa Klinfueng: Performed the experiments.

297 Natthinee Sudhinaraset, Nasamon Wanlapakorn, Juthathip Mongkolsapaya, Sittisak Honsawek,  
298 Yong Poovorawan: Conceived and designed the experiments; Contributed reagents, materials,  
299 analysis tools or data.

300 **Declaration of interests statement**

301 The authors declare that they have no conflict of interest.

302 **Funding Statement**

303 This work was supported by the Health Systems Research Institute (HSRI), the National  
304 Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology,  
305 Chulalongkorn University and King Chulalongkorn Memorial Hospital and was supported by the  
306 Second Century Fund (C2F), Chulalongkorn University. Thaneeya Duangchinda was supported  
307 by the National Center for Genetic Engineering and Biotechnology (BIOTEC Platform No.  
308 P2051613).

309 **Acknowledgments**

310 The authors are grateful to the Center of Excellence in Clinical Virology staffs, all participants,  
311 BJC Big C Foundation and MK restaurant group public Co., Ltd. for helping and supporting this  
312 project. We also thank the Ministry of Public Health, the Chulabhorn Royal Academy, and  
313 Zullig pharma for providing the vaccines for this study.

314 **References**

- 315 Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.  
316 Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous  
317 and heterologous COVID-19 booster vaccines in healthy adults after a two-dose  
318 AZD1222 vaccination. *Int J Infect Dis* 2022a; 122:793–801.
- 319 Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et  
320 al. Neutralizing activities against the Omicron variant after a heterologous booster in  
321 healthy adults receiving two doses of CoronaVac vaccination. *J Infect Dis* 2022b;  
322 226:1372-1381.
- 323 Centers for Disease Control and Prevention, Interim Clinical Considerations for Use of COVID-  
324 19 Vaccines Currently Approved or Authorized in the United States-Centers for Disease  
325 Control and Prevention. [https://www.cdc.gov/vaccines/covid-19/clinical-](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#booster-dose)  
326 [considerations/interim-considerations-us.html#booster-dose](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#booster-dose). (Accessed 26 August 2022).
- 327 Cerqueira-Silva T, De Araujo Oliveira V, Paixão ES, Júnior JB, Penna GO, Werneck GL, et al.  
328 Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the  
329 Omicron period in Brazil. *Nat Commun* 2022a;13:4154.
- 330 Cerqueira-Silva T, Katikireddi SV, De Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES,  
331 et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. *Nat*  
332 *Med* 2022b; 28:838–43.
- 333 Chen L-L, Chu AW-H, Zhang RR-Q, Hung IF-N, To KK-W. Serum neutralisation of the SARS-  
334 CoV-2 omicron sublineage BA.2. *Lancet Microbe* 2022;3:e404.

- 335 Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, et al. Plaque-neutralizing antibody to  
336 BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac  
337 vaccines, natural infection, and breakthrough infection. *J Clin Virol* 2022;156:105273.
- 338 Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-  
339 2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* 2021;  
340 27:2025–31.
- 341 Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence  
342 for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 2021; 39:4423–8.
- 343 Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, et al. mRNA-1273 and  
344 BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2  
345 omicron variant. *Cell Rep Med* 2022; 33:100529.
- 346 Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, et al. Vaccine-induced binding  
347 and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2  
348 booster. *J Med Virol* 2022. doi: 10.1002/jmv.28164.
- 349 Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et  
350 al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and  
351 mRNA COVID-19 Vaccines in fully immunized healthy adults with inactivated vaccine.  
352 *Vaccines* 2022a; 10:86.
- 353 Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, et al.  
354 Comparison of the reactogenicity and immunogenicity of a reduced and standard booster  
355 dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated  
356 vaccine. *Vaccine* 2022b; 40:5657–63.


- 357 Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing  
358 antibody levels are highly predictive of immune protection from symptomatic SARS-  
359 CoV-2 infection. *Nat Med* 2021;27:1205–11.
- 360 Kimura I, Yamasoba D, Tamura T, Nao N, Oda Y, Mitoma S, et al. Virological characteristics of  
361 the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5. Cold  
362 Spring Harbor Laboratory; 2022.
- 363 Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of vaccine-induced  
364 protection against SARS-CoV-2. *Vaccines* 2021;9:238.
- 365 Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-  
366 CoV-2: A comparative computational study of spike protein. *J Med Virol* 2022;94:1641-  
367 1649.
- 368 Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, et al. Neutralization of Omicron BA.1,  
369 BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. *Nat Commun*  
370 2022;13:3602.
- 371 Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of immunogenicity  
372 after seven COVID-19 vaccines given as third dose boosters following two doses of  
373 ChAdOx1 nCov-19 or BNT162b2 in the UK: Three-month analyses of the COV-BOOST  
374 trial. *J Infect* 2022; 84:795–813.
- 375 Lu L, Mok BWY, Chen LL, Chan JMC, Tsang OTY, Lam BHS, et al. Neutralization of Severe  
376 Acute Respiratory Syndrome Coronavirus 2 Omicron variant by sera from BNT162b2 or  
377 CoronaVac vaccine recipients. *Clin Infect Dis* 2022;75:e822–e6.

- 378 Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-  
379 CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. *Science*  
380 2022;375:678–80.
- 381 Paschold L, Klee B, Gottschick C, Willscher E, Diexer S, Schultheiß C, et al. Rapid  
382 Hypermutation B cell trajectory recruits previously primed B Cells Upon Third SARS-  
383 Cov-2 mRNA Vaccination. *Front Immunol* 2022;13:876306.
- 384 Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al.  
385 Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*  
386 2022;602:671–5.
- 387 Qu P, Faraone JN, Evans JP, Zheng Y-M, Yu L, Ma Q, et al. Durability of booster mRNA  
388 vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. *New Engl J Med*  
389 2022;387:1329–31.
- 390 Ranzani OT, Hitchings MDT, De Melo RL, De França GVA, Fernandes CDFR, Lind ML, et al.  
391 Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous  
392 boosters against Omicron in Brazil. *Nat Commun* 2022; 13:5536.
- 393 Sinovac: CoronaVac–COVID19 Vaccine Tracker. Available from:  
394 <https://covid19.trackvaccines.org/vaccines/7/>. (Accessed 05 October 2022).
- 395 Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Continued  
396 emergence, and evolution of Omicron in South Africa: New BA.4 and BA.5 lineages.  
397 *medRxiv [Preprint]* 2022. <https://doi.org/10.1101/2022.05.01.22274406>

- 398 Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic  
399 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*  
400 2022;603:679–86.
- 401 Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of  
402 the SARS-CoV-2 Omicron BA.2 spike. *Cell* 2022; 185:2103–15.e19.
- 403 Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z, et al. Immunogenicity, durability, and safety of  
404 an mRNA and three platform-based COVID-19 vaccines as a third dose following two  
405 doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase  
406 2 trial. *eClinicalMedicine* 2022;54:101680.
- 407 Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and  
408 vaccine effectivity. *J Med Virol* 2022.




409 **Figure captions and Tables**




410

411 **Figure 1. Diagram of recruited participants and study groups.** In our previous study, 334  
 412 participants who had completed two injections of CoronaVac were enrolled and received a single  
 413 booster dose of including BBIBP (n=57), AZD1222 (n=55), BNT162b2 (n=54), half-dose  
 414 BNT162b2 (n=59), mRNA-1273 (n=58), or half-dose mRNA-1273 (n=51) at Day 28 after  
 415 booster timepoint. This extended study, a total of 187 matched individuals including those  
 416 receiving BBIBP (n=24), AZD1222 (n=28), BNT162b2 (n=25), half-dose BNT162b2 (n=37),  
 417 mRNA-1273 (n=39), or half-dose mRNA-1273 (n=34) who completed day 90 to 120 follow up  
 418 timepoints were eligible for final analysis of binding and neutralizing antibodies.



419 **Figure 2: Neutralizing activities against wild type, Omicron BA.2, and BA.4/5 variants at**  
420 **day 90 to 120 post-boosted using a surrogate virus neutralization test.** A subset of samples  
421 (n=20/group) from BBIBP, AZD1222, BNT162b, half-dose BNT162b2, mRNA-1273, and half-  
422 dose mRNA-1273 groups was randomly selected to test for sVNT. **(A)** Neutralizing activities  
423 against the SARS-CoV-2 wild type are shown as %inhibition and **(B)** Neutralizing activities  
424 against the SARS-CoV-2 Omicron variant (BA.2) are shown as %inhibition **(C)** Neutralizing  
425 activities against the SARS-CoV-2 Omicron variant (BA.4/5) are shown as %inhibition. Median  
426 values with interquartile ranges (IQRs) are denoted as horizontal bars. The dotted lines designate  
427 cutoff values at 35% for wild type and 30% for Omicron BA.2 and BA.5 subvariants.  
428



429

430 **Figure 3. Comparison of neutralizing antibody titers against Omicron BA.1 and BA.2**

431 **between day 28 and day 90 to 120 after booster vaccination.** A subset of samples

432 (n=20/group) from AZD1222, BNT162b, and mRNA-1273 groups was randomly selected for

433 testing of the focus reduction neutralization test (FRNT50) against SARS-CoV-2 Omicron

434 BA.1 and BA.2 subvariant. Each data point represents an individual who received a booster

435 vaccine, including the viral vector vaccine, AZD1222 (orange), the mRNA vaccine,

436 BNT162b2 (yellow), or mRNA-1273 (blue). The error bars present GMT. Values below the

437 limit were substituted with a titer of 10. The dotted lines designate cutoff values at 1:20.

438

439 **Table 1.** Demographics and baseline characteristics of the enrolled participants.

	<b>Total</b>	<b>BBIBP</b>	<b>AZD1222</b>	<b>BNT162b2</b>	<b>Half BNT162b2</b>	<b>mRNA-1273</b>	<b>Half mRNA-1273</b>
<b>Total number (n)</b>	187	24	28	25	37	39	34
<b>Mean age (range) year</b>	40.9 (20-69)	43.7 (31-64)	45.0 (20-62)	40.8 (22-55)	40.6 (20-63)	37.0 (21-57)	40.6 (20-69)
<b>Sex</b>							
<b>Male (%)</b>	88/187 (47.1%)	12/24 (50.0%)	10/28 (35.7%)	17/25 (68.0%)	16/37 (43.2%)	18/39 (46.2%)	15/34 (44.1%)
<b>Female (%)</b>	99/187 (52.9%)	12/24 (50.0%)	18/28 (64.3%)	8/25 (32.0%)	21/37 (56.8%)	21/39 (53.8%)	19/34 (55.9%)
<b>Underlying disease (%)</b>							
<b>Allergy</b>	12/187 (6.4%)	1/24 (4.2%)	2/28 (7.1%)	1/25 (4.0%)	2/37 (5.4%)	3/39 (7.7%)	3/34 (8.8%)
<b>Cardiovascular diseases</b>	3/187 (1.6%)	1/24 (4.2%)	2/28 (7.1%)	-	-	-	-
<b>Diabetes Mellitus</b>	10/187 (5.3%)	1/24 (4.2%)	4/28 (14.3%)	2/25 (8.0%)	2/37 (5.4%)	1/39 (2.6%)	-
<b>Dyslipidemia</b>	3/187 (1.6%)	1/24 (4.2%)	1/28 (3.6%)	1/25 (4.0%)	-	-	-
<b>Hypertension</b>	15/187 (8.0%)	1/24 (4.2%)	3/28 (10.7%)	2/25 (8.0%)	4/37 (10.8%)	3/39 (7.7%)	2/34 (5.9%)
<b>Thyroid</b>	3/187 (1.6%)	1/24 (4.2%)	-	-	-	1/39 (2.6%)	1/34 (2.9%)
<b>Other (Gout, Asthma, COPD, etc.)</b>	10/187 (5.3%)	2/24 (8.3%)	1/28 (3.6%)	-	2/37 (5.4%)	2/39(5.1%)	3/34 (8.8%)
<b>Interval between the 2<sup>nd</sup> dose and the booster dose</b>	160.6 (115-237)	166.6 (115-197)	153.6 (130-191)	144.2 (120-166)	162.3 (148-213)	168.5 (148-237)	163.5 (150-210)
<b>Follow-up</b>							
<b>Third visit</b>							
<b>Mean (range) day</b>	28.2 (22-36)	29.0 (25-35)	27.9 (22-29)	28.1 (28-30)	28.3 (27-30)	27.7 (27-32)	28.6 (28-36)
<b>Fourth visit</b>							
<b>Mean (range) day</b>	100.1 (86-127)	93.3 (89-113)	120 (117-121)	120.6 (119-127)	92.8 (90-106)	91.5 (89-102)	91.3 (86-95)

441 **Table 2.** Measurement of GMTs and GMRs (with 95% confidence intervals) of total RBD Ig (U/mL) and anti-RBD IgG (BAU/mL)  
 442 compared between day 28, and day 90–120 in each vaccine regimen.

	<b>BBIBP</b> (n=24)	<b>AZD1222</b> (n=28)	<b>BNT162b2 (II)</b> (n=25)	<b>Half BNT162b2</b> (n=37)	<b>mRNA-1273</b> (n=39)	<b>Half-dose mRNA-1273</b> (n=34)
<b>SARS-CoV-2 total RBD Ig, (U/mL), GMT (95% CI)</b>						
Day 28	1231 (891-1699)	10766 (8235-14074)	21240 (16478-27378)	22345 (18596-26850)	36845 (29827-45513)	28087 (24041-32813)
Day 90	620 (425-904)	3984 (3047-5209)	5514 (4045-7517)	9722 (7937-11909)	10853 (8861-13292)	10587 (8724-12848)
Day 90–120/28 ratio (GMR)	0.50 (0.41-0.61)	0.39 (0.33-0.45)	0.26 (0.22-0.30)	0.44 (0.39-0.49)	0.30 (0.27-0.32)	0.38 (0.34-0.42)
<i>P</i> -value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
(Between D28 and D90–120)						
%Reduction	50.4%	70.0%	74.0%	56.5%	69.8%	62.0%
<b>SARS-CoV-2 anti-RBD IgG, (BAU/mL), GMT (95% CI)</b>						
Day 28	175 (127-241)	1618 (1256-2082)	3708 (2984-4607)	4351 (3682-5141)	7264 (6056-8714)	5636 (4783-6641)
Day 90	84.9 (59.4-121)	623 (481-808)	917 (690-1219)	1743 (1405-2162)	1942 (1594-2365)	1985 (1602-2459)
Day 90–120/28 ratio (GMR)	0.49 (0.43-0.55)	0.39 (0.32-0.45)	0.25 (0.21-0.29)	0.40 (0.36-0.45)	0.27 (0.24-0.31)	0.35 (0.31-0.40)
<i>P</i> -value	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
(Between D28 and D90–120)						
%Reduction	51.5%	61.5%	75.3%	59.9%	73.3%	64.8%

443